5 Most Profitable Biotech Stocks Today

2. Johnson & Johnson (NYSE:JNJ)

Latest TTM Net Income Figures: $17.9 billion

Johnson & Johnson (NYSE:JNJ) is another global healthcare giant. The firm is a key player in the biotechnology market through its subsidiary Janssen Biotech which develops treatments for cancer, heart diseases, immune system disorders, and other ailments. Even as other big pharma firms falter, Johnson & Johnson (NYSE:JNJ) is doing quite well and has beaten analyst EPS estimates in all four of its latest quarters.

Insider Monkey dug through 910 hedge funds for their June quarter of 2023 investments and discovered that 88 had invested in Johnson & Johnson (NYSE:JNJ). Ken Fisher’s Fisher Asset Management is the firm’s biggest hedge fund investor, through a stake worth $1.1 billion.

Follow Johnson & Johnson (NYSE:JNJ)